期刊文献+

老年急性心肌梗死患者介入治疗联合替罗非班的疗效及安全性研究 被引量:7

下载PDF
导出
摘要 目的:观察老年急性心肌梗死患者经皮冠状动脉介入治疗联合应用替罗非班的疗效及安全性。方法:选取急性心肌梗死并行急诊介入治疗的老年患者78例,年龄65~81岁,平均(71.6±8.3)岁,随机分为替罗非班组(n=36)和对照组(n=42)。观察两组患者的TIMI3级血流获得情况、术后1hST段回落情况、左室射血分数变化以及主要不良心脏事件及出血的发生率。结果:替罗非班组的TIMI3级血流获得率、术后1h内ST段回落比例及左室射血分数均明显高于对照组(P<0.05),而不良心脏事件发生率低于对照组(P<0.05),出血的发生率两组间比较差异无统计学意义(P>0.05)。结论:老年急性心肌梗死患者介入治疗联合应用替罗非班可改善患者预后,同时并不增加出血风险。
出处 《实用医学杂志》 CAS 北大核心 2011年第14期2579-2580,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献8

二级参考文献66

  • 1杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量:91
  • 2[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 3[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
  • 4[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
  • 5[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
  • 6[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
  • 7[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
  • 8[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
  • 9[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
  • 10[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.

共引文献232

同被引文献55

  • 1王咏梅,陈美红,金建芬.老年急性心肌梗死患者急诊冠脉介入治疗的护理[J].心脑血管病防治,2005,5(4):59-59. 被引量:2
  • 2杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量:91
  • 3Razakjr O A, Tan H C, Yip W L, et al. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention [J]. J Interv Cardiol, 2005,18 ( 1 ) : 33-37.
  • 4Silber S, Albertsson P, Aviles F F, et al. Guidelines for percutane0us coronary interventions. The task force for pereutaneous coronary interventions of the european society of cardiology[J]. Eur Heart J, 2005,26(8):804-847.
  • 5Yip H K, Chen M C, Chang H W, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow- flow and no-reflow phenomenon[J]. Chest, 2002,122 (4) : 1322-1332.
  • 6Galiuto L, Garramone B, Burzotta F, et al. Thrombus aspiration reduce microvascular obstruction after primary coronary intervention [J]. J Am Coil Cardiol, 2006,48(7): 1355-1360.
  • 7Niccoli G, Kharbanda R K, Crea F, et al. No-reflow: again prevention is better than treatment [J]. Eur Heart J, 2010,31 (20) : 2449-2455.
  • 8Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abeiximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial [J]. J Am Coll Cardiol, 2006,47(3):522-528.
  • 9Wu T G, Zhao Q, Huang W G, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome[J]. Circ J, 2008,72 (10) : 1605-1609.
  • 10Valqimiqli M, Percoco C, Malaqutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction : a randon:ized trial[J]. JAMA, 2005,293 ( 17 ) : 2109-2117.

引证文献7

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部